Quality of Informed Consent in Mammography Screening—The Polish Experience
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Limitations
6. Conclusions
- Consent for mammography in many cases did not meet the content (including information on overdiagnosis and false-positive results) and formal criteria, which reduced its quality. Effort should be made to raise the standard of obtaining consent for mammography screening.
- The main motivations for women to undergo mammography screening were to reduce their concerns about observed risk factors and to avail of the free screening.
- Effort should be made to balance the benefit–risk ratio. Overestimation of benefits and underestimation of risks in mammography perception can lead to unrealistic expectations and emotional overburden. As the process of obtaining consent is difficult and time consuming, it would be best to combine some elements of it, e.g., by sending patients balanced information along with the screening invitation.
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Gajewski, P.; Szczeklik, A. Interna Szczeklika Podręcznik Chorób Wewnętrznych; Wyd. 8; Medycyna Praktyczna: Kraków, Poland, 2017; ISBN 978-83-7430-517-4. [Google Scholar]
- Youlden, D.R.; Cramb, S.M.; Dunn, N.A.; Muller, J.M.; Pyke, C.M.; Baade, P.D. The descriptive epidemiology of female breast cancer: An international comparison of screening, incidence, survival and mortality. Cancer Epidemiol. 2012, 36, 237–248. [Google Scholar] [CrossRef] [Green Version]
- Ministerstwo Zdrowia. Program Profilaktyki Raka Piersi. Available online: Https://www.gov.pl/web/zdrowie/program-profilaktyki-raka-piersi-mammografia (accessed on 1 February 2021).
- Data on the Prophylactic Programmes Fulfilment, Made Available by the National Health Fund. Available online: Https://www.nfz.gov.pl/dla-pacjenta/programy-profilaktyczne/dane-o-realizacji-programow/ (accessed on 4 March 2021).
- Bhatt, A. Improving quality of informed consent in clinical research. J. Postgrad. Med. 2015, 61, 221–222. [Google Scholar] [CrossRef] [PubMed]
- Chane, W.; Birhanu, B.; Suga, Y. Quality of informed consent among patients who underwent major surgical procedure in a tertiary care hospital, Addis Ababa, Ethiopia. Open Access Surg. 2020, 13, 27–33. [Google Scholar] [CrossRef]
- Minnies, D.; Hawkridge, T.; Hanekom, W.; Ehrlich, R.; London, L.; Hussey, G. Evaluation of the quality of informed consent in a vaccine field trial in a developing country setting. BMC Med. Ethics 2008, 9, 15. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bolcato, M.; De Salvia, A.; Rodriguez, D.; Aprile, A. Is the Italian consent to transfusion really informed? A medico-legal analysis between old ghosts and new evidence. Transfus. Apher. Sci. 2020, 59, 102823. [Google Scholar] [CrossRef]
- Jørgensen, K.J.; Gøtzsche, P.C. Content of invitations for publicly funded screening mammography. BMJ 2006, 332, 538–541. [Google Scholar] [CrossRef] [PubMed]
- Gummersbach, E.; Piccoliori, G.; Zerbe, C.O.; Altiner, A.; Othman, C.; Rose, C.; Abholz, H.H. Are women getting relevant information about mammography screening for an informed consent? A critical appraisal of information brochures used for screening invitation in Germany, Italy, Spain and France. Eur. J. Public Health 2010, 20, 409–414. [Google Scholar] [CrossRef] [Green Version]
- Bogusz, R.; Charzyńska-Gula, M.; Majewska, A.; Gałęziowska, E. Wiedza kobiet w wieku okołomenopauzalnym na temat profilaktyki raka piersi. Med. Ogólna Nauk. Zdrowiu 2013, 19, 523–529. [Google Scholar]
- Zapka, J.G.; Geller, B.M.; Bulliard, J.L.; Fracheboud, J.; Sancho-Garnier, H.; Ballard-Barbash, R. IBSN Communications Working Group, Print information to inform decisions about mammography screening participation in 16 countries with population based programs. Patient Educ. Couns. 2006, 63, 126–137. [Google Scholar] [CrossRef]
- Ballesteros-Peña, S.; Gavilán-Moral, E. Contenido de los documentos informativos dirigidos a las mujeres sobre el cribado de cáncer de mama en España [Content of official addressed to women informative documents about breast cancer screening in Spain]. Rev. Española Salud Pública 2018, 92, e201810076. [Google Scholar]
- Brewer, N.T.; Salz, T.; Lillie, S.E. Systematic review: The long-term effects of false-positive mammograms. Ann. Intern. Med. 2007, 146, 502–510. [Google Scholar] [CrossRef] [PubMed]
- Salz, T.; Richman, A.R.; Brewer, N.T. Meta-analyses of the effect of false-positive mammograms on generic and specific psychosocial outcomes. Psychooncology 2010, 19, 1026–1034. [Google Scholar] [CrossRef] [PubMed]
- Molina, Y.; Beresford, S.A.; Thompson, B. Psychological outcomes after a false positive mammogram: Preliminary evidence for ethnic differences across time. J. Racial Ethn. Health Disparities 2017, 4, 123–133. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Le, M.T.; Mothersill, C.E.; Seymour, C.B.; McNeill, F.E. Is the false-positive rate in mammography in North America too high? Br. J. Radiol. 2016, 89, 20160045. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lameijer, J.R.; Voogd, A.C.; Pijnappel, R.M.; Setz-Pels, W.; Broeders, M.J.; Tjan-Heijnen, V.C.; Duijm, L.E. Delayed breast cancer diagnosis after repeated recall at biennial screening mammography: An observational follow-up study from the Netherlands. Br. J. Cancer 2020, 123, 325–332. [Google Scholar] [CrossRef]
- Lee, J.M.; Lowry, K.P.; Cott Chubiz, J.E.; Swan, J.S.; Motazedi, T.; Halpern, E.F.; Tosteson, A.N.A.; Gazelle, G.S.; Donelan, K. Breast cancer risk, worry, and anxiety: Effect on patient perceptions of false-positive screening results. Breast 2020, 50, 104–112. [Google Scholar] [CrossRef] [Green Version]
- Ong, M.S.; Mandl, K.D. National expenditure for false-positive mammograms and breast cancer overdiagnoses estimated at $4 billion a year. Health Aff. 2015, 34, 576–583. [Google Scholar] [CrossRef]
- Pauwels, E.K.; Foray, N.; Bourguignon, M.H. Breast cancer induced by X-Ray mammography screening? A review based on recent understanding of low-dose radiobiology. Med. Princ. Pract. 2016, 25, 101–109. [Google Scholar] [CrossRef]
- Miglioretti, D.L.; Lange, J.; van den Broek, J.J.; Lee, C.I.; van Ravesteyn, N.T.; Ritley, D.; Hubbard, R.A. Radiation-induced breast cancer incidence and mortality from digital mammography screening: A modeling study. Ann. Intern. Med. 2016, 164, 205–214. [Google Scholar] [CrossRef]
- Corcos, D. Breast cancer incidence as a function of the number of previous mammograms: Analysis of the NHS screening programme. bioRxiv 2017. [Google Scholar] [CrossRef]
- Krajowy Rejestr Nowotworów [online]. Available online: http://onkologia.org.pl/nowotwory-piersi-kobiet/ (accessed on 29 January 2021).
- Autier, P.; Boniol, M.; Koechlin, A.; Pizot, C.; Boniol, M. Effectiveness of and overdiagnosis from mammography screening in the Netherlands: Population based study. BMJ 2017, 359, j5224. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lund, E.; Nakamura, A.; Thalabard, J.C. No overdiagnosis in the Norwegian breast cancer screening program estimated by combining record linkage and questionnaire information in the Norwegian Women and Cancer study. Eur. J. Cancer 2018, 89, 102–112. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lynge, E.; Beau, A.B.; Christiansen, P.; von Euler-Chelpin, M.; Kroman, N.; Njor, S.; Vejborg, I. Overdiagnosis in breast cancer screening: The impact of study design and calculations. Eur. J. Cancer 2017, 80, 26–29. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Glasziou, P.; Houssami, N. The evidence base for breast cancer screening. Prev. Med. 2011, 53, 100–102. [Google Scholar] [CrossRef]
- Welch, H.G.; Black, W.C. Overdiagnosis in cancer. J. Natl. Cancer Inst. 2010, 102, 605–613. [Google Scholar] [CrossRef] [Green Version]
- Zackrisson, S.; Andersson, I.; Janzon, L.; Manjer, J.; Garne, J.P. Rate of overdiagnosis of breast cancer 15 years after end of Malmo mammographic screening trial: Follow-up study. BMJ 2006, 332, 689–692. [Google Scholar] [CrossRef] [Green Version]
- Autier, P.; Boniol, M. Mammography screening: A major issue in medicine. Eur J. Cancer 2018, 90, 34–62. [Google Scholar] [CrossRef]
- Wu, W.Y.; Törnberg, S.; Elfström, K.M.; Liu, X.; Nyström, L.; Jonsson, H. Overdiagnosis in the population-based organized breast cancer screening program estimated by a non-homogeneous multi-state model: A cohort study using individual data with long-term follow-up. Breast Cancer Res. 2018, 20, 153. [Google Scholar] [CrossRef]
- Fann, J.C.; Chang, K.J.; Hsu, C.Y.; Yen, A.M.; Yu, C.P.; Chen, S.L.; Kuo, W.H.; Tabár, L.; Chen, H.H. Impact of Overdiagnosis on Long-Term Breast Cancer Survival. Cancers 2019, 11, E325. [Google Scholar] [CrossRef] [Green Version]
- Zagaja, A.; Pawlikowski, J. Problem nadrozpoznawalności w kontekście dostępu do nowych technologii medycznych. Med. Ogólna Nauk. Zdrowiu 2016, 22, 1–6. [Google Scholar] [CrossRef]
- Kołłątaj, W.; Karwat, I.D.; Kołłataj, B.; Piecewicz-Szczęsna, H.; Sowa, M. Profilaktyka nowotworów u kobiet w Polsce. Sukces czy niepowodzenie? Opinie pacjentów, lekarzy I instytucji odpowiedzialnych za stan zdrowia—Meta analiza. J. Educ. Health Sport 2016, 6, 318–328. [Google Scholar]
- Yu, J.; Nagler, R.H.; Fowler, E.F.; Kerlikowske, K.; Gollust, S.E. Women’s awareness and perceived importance of the harms and benefits of mammography screening: Results from a 2016 national survey. JAMA Intern. Med. 2017, 177, 1381–1382. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Yes (%) | No (%) | I Do Not Remember (%) | |
---|---|---|---|
Consent was obtained in comfortable conditions (peace, quiet). | 72.4 | 10.3 | 17.3 |
Prior to screening, I was asked to sign a consent form. | 61.9 | 19.4 | 18.7 |
I received information materials on screening (leaflets, brochures, etc.). | 64.9 | 16.6 | 18.5 |
Prior to providing my consent, I was informed orally about the benefits associated with mammography. | 70.7 | 7 | 22.3 |
Prior to providing my consent, I was informed orally about the risks associated with mammography. | 34.9 | 41.9 | 23.2 |
The person obtaining consent made sure that I understood the information provided (asked questions, feedback, etc.) before obtaining my signature on the consent form. | 29.7 | 29.3 | 41 |
I had the opportunity to ask questions prior to undergoing screening. | 52.4 | 17.5 | 30.1 |
Yes | No | I Do Not Remember | ||||
---|---|---|---|---|---|---|
N | % | N | % | N | % | |
Before screening, I was informed of its benefits e.g., greater effectiveness of treatment if cancer is detected at an earlier stage. | 292 | 61.5 | 56 | 11.8 | 127 | 26.7 |
Before mammography, I was informed of the risk of ambiguous results. | 119 | 25 | 144 | 30.3 | 212 | 44.7 |
Before mammography, I was informed of the risk of an erroneous result suggesting the presence of breast cancer despite its absence. | 145 | 30.5 | 144 | 30.5 | 186 | 39 |
Before mammography, I was informed of the risk of an erroneous result suggesting no breast cancer despite its actual presence (or the risk of missing a cancer). | 132 | 27.8 | 169 | 35.6 | 174 | 36.6 |
Before mammography, I was informed of the possibility of my developing cancer between screening tests. | 207 | 43.6 | 132 | 27.8 | 136 | 28.6 |
Before mammography, I was informed of the possibility of the detection of minor changes that carry no risk of death (overdiagnosis). | 252 | 53 | 94 | 19.8 | 129 | 27.2 |
Before mammography, I was informed of the recommendation for self-examination. | 304 | 64 | 31 | 6.5 | 140 | 29.5 |
Variable | M | SD | F | p | Post Hoc | Effect Size |
---|---|---|---|---|---|---|
Age | ||||||
50–60 (1) | 7.05 | 1.89 | 3.215 | 0.041 | 1 > 3 | 0.013 |
61–70 (2) | 7.01 | 1.98 | ||||
70+ (3) | 6.46 | 2.08 | ||||
Place of residence | ||||||
Countryside (1) | 7.19 | 1.96 | 5.655 | 0.004 | 1 > 3; 2 > 3 | 0.023 |
City with up to 100 thousand (2) | 7.18 | 1.90 | ||||
City with over 100 thousand (3) | 6.58 | 1.97 | ||||
Education | ||||||
Primary education (1) | 7.16 | 1.80 | 1.330 | 0.264 | – | 0.008 |
Vocational (2) | 7.09 | 1.99 | ||||
High school (3) | 6.88 | 1.96 | ||||
Higher (4) | 6.57 | 1.93 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Zagaja, A.; Bogusz, R.; Sak, J.; Wiechetek, M.; Pawlikowski, J. Quality of Informed Consent in Mammography Screening—The Polish Experience. Int. J. Environ. Res. Public Health 2022, 19, 6735. https://doi.org/10.3390/ijerph19116735
Zagaja A, Bogusz R, Sak J, Wiechetek M, Pawlikowski J. Quality of Informed Consent in Mammography Screening—The Polish Experience. International Journal of Environmental Research and Public Health. 2022; 19(11):6735. https://doi.org/10.3390/ijerph19116735
Chicago/Turabian StyleZagaja, Anna, Renata Bogusz, Jarosław Sak, Michał Wiechetek, and Jakub Pawlikowski. 2022. "Quality of Informed Consent in Mammography Screening—The Polish Experience" International Journal of Environmental Research and Public Health 19, no. 11: 6735. https://doi.org/10.3390/ijerph19116735
APA StyleZagaja, A., Bogusz, R., Sak, J., Wiechetek, M., & Pawlikowski, J. (2022). Quality of Informed Consent in Mammography Screening—The Polish Experience. International Journal of Environmental Research and Public Health, 19(11), 6735. https://doi.org/10.3390/ijerph19116735